GNRH1 and prostate carcinoma: Relugolix is an oral highly selective LHRH antagonist given daily that has been shown to achieve androgen deprivation in both phase I9 and phase II10 trials and was finally approved by the FDA in the phase III HERO trial.2 The HERO trial enrolled patients with castration-sensitive prostate cancer and compared their sustained castration rate at 48 weeks to leuprolide.